Merck Eprova AG, Switzerland: Merck Eprova AG (www.merckeprova.com) has developed a proprietary process to manufacture the enantiomerically pure cationic lipid DOTAP Chloride. Merck Eprova AG has granted PDS Biotechnology an exclusive commercial license to utilize the chiral DOTAP in Versamune™-HPV and other products based on the Versamune™ technology. The use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity compared to the racemate. Merck Eprova AG will be providing enantiomerically pure DOTAP Chloride manufactured under cGMP for use in clinical and commercial drug products developed with PDS Biotechnology’s Versamune™ nanoparticle technology.
Nanotechnology Characterization Lab (NCL)/ National Cancer Institute (NCI): PDS Biotechnology Corporation has been selected as an affiliate of the NCL. The NCL is a collaboration between the NCI, Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST). The NCL’s goal is to select the most promising cancer nanotechnologies and work with the companies to get their products rapidly through regulatory submissions with the FDA at no cost to the selected companies. PDS is collaborating with the NCL to develop Versamune™ –HPV.
University of North Carolina, Chapel Hill: PDS has a sponsored research agreement with Dr. Leaf Huang’s laboratory at UNC to develop Versamune™ –HPV and Versamune™ –melanoma. Dr. Huang, a founder of PDS Biotechnology and member of the scientific advisory board, is the inventor of the Versamune™ technology. Significant progress in understanding the benefits and mechanism of action of the technology have resulted.